Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials

References

• Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379(12):1150–1160.
   PubMed Web of Science ®Google Scholar
• Hart A, Singh D, Brown SJ, et al. Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review. Clin Transplant. 2021;35(7):e14320.
   PubMed Web of Science ®Google Scholar
• Irish W, Nickerson P, Astor BC, Irish W, Nickerson P, Astor BC, et al. Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation. 2021;105(3):648–659.
   PubMed Web of Science ®Google Scholar
• Hart A, Schladt DP, Matas AJ, et al. Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection - the long-term deterioration of kidney allograft function (DeKAF) prospective cohort study. Clin Transplant. 2021;35(7):e14337.
   PubMed Web of Science ®Google Scholar
• Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–399.
   PubMed Web of Science ®Google Scholar
• Mayrdorfer M, Liefeldt L, Wu K, et al. Exploring the complexity of death-censored kidney allograft failure. J Am Soc Nephrol. 2021;32(6):1513–1526.
   PubMed Web of Science ®Google Scholar
• Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003;3(6):708–714.
   PubMed Web of Science ®Google Scholar
• Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant. 2018;18(4):785–795.
   PubMed Web of Science ®Google Scholar
• Loupy A, Haas M, Roufosse C, et al. The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–2331.
   PubMed Web of Science ®Google Scholar
• Wiebe C, Rush DN, Nevins TE, et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol. 2017;28(11):3353–3362.
   PubMed Web of Science ®Google Scholar
• Schinstock CA, Mannon RB, Budde K, et al. recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion society working group. Transplantation. 2020;104(5):911–922.
   PubMed Web of Science ®Google Scholar
• Roufosse C, Becker JU, Rabant M, et al. Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation. Transpl Int. 2022;35:10140.
   PubMed Web of Science ®Google Scholar
• Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8(11):670–678.
   PubMed Web of Science ®Google Scholar
• Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection. Trends Mol Med. 2015;21(5):319–329.
   PubMed Web of Science ®Google Scholar
• Venner JM, Hidalgo LG, Famulski KS, et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15(5):1336–1348.
   PubMed Web of Science ®Google Scholar
• Callemeyn J, Lamarthee B, Koenig A, et al. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int. 2022;101(4):692–710.
   PubMed Web of Science ®Google Scholar
• Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant. 2013;18(4):430–435.
   PubMed Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Kainz A, et al. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. Lancet. 2019;393(10174):910–917.
   PubMed Web of Science ®Google Scholar
• Koenig A, Chen CC, Marcais A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nat Commun. 2019;10(1):5350.
   PubMedGoogle Scholar
• Callemeyn J, Senev A, Coemans M, et al. Missing self-induced microvascular rejection of kidney allografts: a population-based study. J Am Soc Nephrol. 2021;32(8):2070–2082.
   PubMed Web of Science ®Google Scholar
• Koslik MA, Friebus-Kardash J, Heinemann FM, et al. Differential treatment effects for renal transplant recipients with DSA-positive or DSA-negative antibody-mediated rejection. Front Med (Lausanne). 2022;9:816555.
   PubMed Web of Science ®Google Scholar
• Wan SS, Ying TD, Wyburn K, et al. The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation. 2018;102(4):557–568.
   PubMed Web of Science ®Google Scholar
• Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant. 2011;11(5):896–906.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.
   PubMedGoogle Scholar
• Kirubakaran MG, Disney AP, Norman J, et al. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation. 1981;32(2):164–165.
   PubMed Web of Science ®Google Scholar
• Soulillou JP, Guyot C, Guimbretiere J, et al. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron. 1983;35(3):158–162.
   PubMed Web of Science ®Google Scholar
• Allen NH, Dyer P, Geoghegan T, et al. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation. 1983;35(5):425–428.
   PubMed Web of Science ®Google Scholar
• Bonomini V, Vangelista A, Frasca GM, et al. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs. 1985;31:698–703.
   PubMedGoogle Scholar
• Böhmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant. 2007;7(1):117–121.
   PubMed Web of Science ®Google Scholar
• GODT. Executive Summary of 2020 Activity Data. WHO-ONT. 2021. [cited 2022 Feb 25]. Available from: http://www.transplant-observatory.org/2020-international-activities-report/
   Google Scholar
• USRDS. 2021 Annual Report. USRDS Coordinating Center. 2021. [cited 2022 Feb 25]. Available from: https://adr.usrds.org/2021/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities
   Google Scholar
• Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385(8):729–743.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant. 2002;2(10):970–974.
   PubMed Web of Science ®Google Scholar
• Perl J. Kidney transplant failure: failing kidneys, failing care? Clin J Am Soc Nephrol. 2014;9(7):1153–1155.
   PubMed Web of Science ®Google Scholar
• Hart A, Zaun D, Itzler R, et al. Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US. J Med Econ. 2021;24(1):1011–1017.
   PubMed Web of Science ®Google Scholar
• NCT03744910. Clazakizumab for the treatment of chronic active antibody mediated rejection in kidney transplant recipients (IMAGINE). Bethesda (MD): U.S. National Library of Medicine; 2018 [ updated 2022 Mar 3; cited 2022 Feb 22]. updated 2022 Mar 3: https://clinicaltrials.gov/ct2/show/NCT03744910
   Google Scholar
• Callemeyn J, Ameye H, Lerut E, et al. Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am J Transplant. 2021;21(7):2413–2423.
   PubMed Web of Science ®Google Scholar
• Böhmig GA, Eskandary F, Doberer K, et al. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int. 2019;32(8):775–788.
   PubMed Web of Science ®Google Scholar
• Huang E, Maldonado AQ, Kjellman C, et al. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant. 2022;22(3):691–697.
   PubMed Web of Science ®Google Scholar
• Jarnum S, Bockermann R, Runstrom A, et al. The bacterial enzyme IdeS cleaves the IgG-type of B cell receptor (BCR), Abolishes BCR-mediated cell signaling, and inhibits memory B cell activation. J Immunol. 2015;195(12):5592–5601.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Jarnum S, Nordahl EA, et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS–A novel therapeutic opportunity. PLoS One. 2015;10(7):e0132011.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442–453.
   PubMed Web of Science ®Google Scholar
• Lonze BE, Tatapudi VS, Weldon EP, et al. IdeS (Imlifidase): a novel agent that cleaves human igg and permits successful kidney transplantation across high-strength donor-specific antibody. Ann Surg. 2018;268(3):488–496.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (highdes). Transplantation. 2021;105(8):1808–1817.
   PubMed Web of Science ®Google Scholar
• Kjellman C, Maldonado AQ, Sjoholm K, et al. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021;21(12):3907–3918.
   PubMed Web of Science ®Google Scholar
• NCT03897205. An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients. Bethesda (MD): U.S. National Library of Medicine; 2019 [ updated 2021 Dec 8; cited 2022 Feb 22]. updated 2021 Dec 8: https://clinicaltrials.gov/ct2/show/NCT03897205
   Google Scholar
• NCT04711850. An long-term follow-up trial of kidney Tx patients treated with imlifidase or pe after an AMR. Bethesda (MD): U.S. National Library of Medicine; 2021 [ updated 2021 Dec 9; cited 2022 Feb 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04711850
   Google Scholar
• Horwitz JK, Chun NH, Heeger PS. Complement and transplantation: from new mechanisms to potential biomarkers and novel treatment strategies. Clin Lab Med. 2019;39(1):31–43.
   PubMed Web of Science ®Google Scholar
• Böhmig GA, Wahrmann M, Eskandary F, et al. Novel approaches to block complement. Transplantation. 2018;102(11):1837–1843.
   PubMed Web of Science ®Google Scholar
• Wahrmann M, Mühlbacher J, Marinova L, et al. Effect of the anti-C1s humanized antibody TNT009 and its parental mouse variant TNT003 on HLA antibody-induced complement activation-a preclinical in vitro study. Am J Transplant. 2017;17(9):2300–2311.
   PubMed Web of Science ®Google Scholar
• Eskandary F, Jilma B, Mühlbacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant. 2018;18(4):916–926.
   PubMed Web of Science ®Google Scholar
• NCT05156710. BIVV020 in prevention and treatment of Antibody-mediated Rejection (AMR). Bethesda (MD): U.S. National Library of Medicine; 2021 [ updated 2022 Feb 17; cited 2022 Feb 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT05156710
   Google Scholar
• Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405–2413.
   PubMed Web of Science ®Google Scholar
• Cornell LD, Schinstock CA, Gandhi MJ, et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant. 2015;15(5):1293–1302.
   PubMed Web of Science ®Google Scholar
• Marks WH, Mamode N, Montgomery RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant. 2019;19(10):2876–2888.
   PubMed Web of Science ®Google Scholar
• NCT01895127. Efficacy and safety of eculizumab for treatment of antibody-mediated rejection following renal transplantation. Bethesda (MD): U.S. National Library of Medicine; 2013 [ updated Sept 21, 2017; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01895127
   Google Scholar
• NCT01327573. Eculizumab therapy for chronic complement-mediated injury in kidney transplantation. Bethesda (MD): U.S. National Library of Medicine; 2011 [ updated Aug 12, 2019; cited Feb 20, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01327573
   Google Scholar
• Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant. 2017;17(3):682–691.
   PubMed Web of Science ®Google Scholar
• Eerhart MJ, Reyes JA, Blanton CL, et al. Complement blockade in recipients prevents delayed graft function and delays antibody-mediated rejection in a nonhuman primate model of kidney transplantation. Transplantation. 2022;106(1):60–71.
   PubMed Web of Science ®Google Scholar
• Vo AA, Zeevi A, Choi J, et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015;99(2):299–308.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Choi J, Aubert O, et al. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. Am J Transplant. 2018;18(12):2955–2964.
   PubMed Web of Science ®Google Scholar
• Viglietti D, Gosset C, Loupy A, et al. C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant. 2016;16(5):1596–1603.
   PubMed Web of Science ®Google Scholar
• NCT01147302. A pilot study to evaluate the use of c1 esterase inhibitor (human) in patients with acute antibody-mediated rejection. Bethesda (MD): U.S. National Library of Medicine; 2010 [ updated Jun 11, 2021; cited Feb 20, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01147302
   Google Scholar
• Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant. 2016;16(12):3468–3478.
   PubMed Web of Science ®Google Scholar
• NCT02547220. A multicenter study to evaluate the efficacy and safety of cinryze® for the treatment of acute antibody-mediated rejection in participants with kidney transplant. Bethesda (MD): U.S. National Library of Medicine; 2015 [ updated 2020 Jul 13; cited 2022 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02547220
   Google Scholar
• NCT03221842. Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection (AMR) in adult renal transplant recipients. Bethesda (MD): U.S. National Library of Medicine; 2017 [ updated Jan 18, 2022; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03221842
   Google Scholar
• Eskandary F, Wahrmann M, Biesenbach P, et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration–a randomized, controlled, cross-over trial. Nephrol Dial Transplant. 2014;29(3):706–714.
   PubMed Web of Science ®Google Scholar
• Doberer K, Bond G, Kläger J, et al. Immunoadsorption combined with membrane filtration to counteract early treatment-refractory antibody-mediated rejection. Blood Purif. 2020;49(5):576–585.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mayerhoffer S, Berlakovich GA, et al. Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. Transplant Int. 2015;28(7):820–827.
   PubMed Web of Science ®Google Scholar
• Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018;18(7):1783–1789.
   PubMed Web of Science ®Google Scholar
• Budde K, Prashar R, Haller H, et al. Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial. J Am Soc Nephrol. 2021;32(12):3252–3264.
   Web of Science ®Google Scholar
• Bray RA, Gebel HM, Townsend R, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant. 2018;18(7):1774–1782.
   PubMed Web of Science ®Google Scholar
• Kumar D, Raynaud M, Chang J, et al. Impact of belatacept conversion on renal function, histology and gene expression in kidney transplant patients with chronic active antibody-mediated rejection. Transplantation. 2021;105(3):660–667.
   PubMed Web of Science ®Google Scholar
• Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6):996–1001.
   PubMed Web of Science ®Google Scholar
• Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007;83(9):1277–1280.
   PubMed Web of Science ®Google Scholar
• Fehr T, Rusi B, Fischer A, et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation. 2009;87(12):1837–1841.
   PubMed Web of Science ®Google Scholar
• Billing H, Rieger S, Süsal C, Billing H, Rieger S, Süsal C, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int. 2012;25(11):1165–1173.
   PubMed Web of Science ®Google Scholar
• Bachelet T, Nodimar C, Taupin JL, et al. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. Clin Transplant. 2015;29(5):439–446.
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant. 2008;8(12):2607–2617.
   PubMed Web of Science ®Google Scholar
• NCT01066689. Impact of treatment with rituximab on the progression of humoral acute rejection after renal transplantation (RITUX-ERAH). Bethesda (MD): U.S. National Library of Medicine; 2010 [ updated Feb 10, 2010; cited Feb 20, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01066689
   Google Scholar
• Sautenet B, Blancho G, Buchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016;100(2):391–399.
   PubMed Web of Science ®Google Scholar
• Bailly E, Ville S, Blancho G, et al. An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int. 2020;33(7):786–795.
   PubMed Web of Science ®Google Scholar
• 2010-023746-67. Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study. Amsterdam Netherlands: EU Clinical Trials Register; 2014 [ updated Dec 4, 2021; cited Feb 25, 2022]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023746-67
   Google Scholar
• Moreso F, Crespo M, Ruiz JC, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018;18(4):927–935.
   PubMed Web of Science ®Google Scholar
• NCT00476164. Study of rituximab to treat chronic renal transplant rejection (RituxiCAN-C4). Bethesda (MD): U.S. National Library of Medicine; 2007 [Cited 2020 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT00476164
   Google Scholar
• Shiu KY, Stringer D, McLaughlin L, et al. Effect of optimized immunosuppression (including rituximab) on anti-donor alloresponses in patients with chronically rejecting renal allografts. Front Immunol. 2020;11:79.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Vieira CA, Book BK, et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4(8):1357–1360.
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360(25):2683–2685.
   PubMed Web of Science ®Google Scholar
• Kamburova EG, van den Hoogen MW, Koenen HJ, et al. Cytokine release after treatment with rituximab in renal transplant recipients. Transplantation. 2015;99(9):1907–1911.
   PubMed Web of Science ®Google Scholar
• NCT03994783. transplant antibody-mediated rejection: guiding effective treatments (TAR:GET-1). Bethesda (MD): U.S. National Library of Medicine; 2019 [ updated Apr 1, 2021; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03994783
   Google Scholar
• Viglietti D, Loupy A, Aubert O, et al. Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol. 2018;29(2):606–619.
   PubMed Web of Science ®Google Scholar
• Budde K, Dürr M. Any progress in the treatment of antibody-mediated rejection? J Am Soc Nephrol. 2018;29(2):350–352.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Ammerman N, Choi J, et al. Interleukin-6: an important mediator of allograft injury. Transplantation. 2020;104(12):2497–2506.
   PubMed Web of Science ®Google Scholar
• Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381–2389.
   PubMed Web of Science ®Google Scholar
• Pottebaum AA, Venkatachalam K, Liu C, et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct. 2020;6(4):e543.
   PubMed Web of Science ®Google Scholar
• Lavacca A, Presta R, Gai C, et al. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant. 2020;34(8):e13908.
   PubMed Web of Science ®Google Scholar
• Noble J, Giovannini D, Laamech R, et al. Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring. Front Med (Lausanne). 2021;8:790547.
   PubMed Web of Science ®Google Scholar
• Massat M, Congy-Jolivet N, Hebral AL, et al. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant. 2021;21(4):1641–1649.
   PubMed Web of Science ®Google Scholar
• Chandran S, Leung J, Hu C, et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transplant. 2021;21(7):2543–2554.
   PubMed Web of Science ®Google Scholar
• NCT03444103. A pilot trial of clazakizumab in late ABMR. Bethesda (MD): U.S. National Library of Medicine; 2018 [ updated Sept 9, 2020; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03444103
   Google Scholar
• Doberer K, Duerr M, Halloran PF, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32(3):708–722.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Ammerman N, Choi J, et al. The role of novel therapeutic approaches for prevention of allosensitization and antibody‐mediated rejection. Am J Transplant. 2020;20(S4):42–56.
   PubMedGoogle Scholar
• Jordan SC, Ammerman N, Choi J, et al. Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep. 2022;7(4):720–731.
   PubMed Web of Science ®Google Scholar
• NCT04561986. TocIlizumab in chronic antibody-mediated rejection in kidney transplant recipients (INTERCEPT). Bethesda (MD): U.S. National Library of Medicine; 2020 [ updated Feb 17, 2022; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04561986
   Google Scholar
• Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant. 2008;8(1):133–143.
   PubMed Web of Science ®Google Scholar
• Walsh RC, Alloway RR, Girnita AL, et al. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012;81(11):1067–1074.
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754–1761.
   PubMed Web of Science ®Google Scholar
• Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation. 2010;90(12):1486–1492.
   PubMed Web of Science ®Google Scholar
• Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation. 2011;91(11):1218–1226.
   PubMed Web of Science ®Google Scholar
• Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27(3):1246–1251.
   PubMed Web of Science ®Google Scholar
• Ejaz NS, Alloway RR, Halleck F, et al. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid Redox Signal. 2014;21(17):2401–2418.
   PubMed Web of Science ®Google Scholar
• NCT01873157. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT). Bethesda (MD): U.S. National Library of Medicine; 2013 [ updated Mar 23, 2017; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01873157
   Google Scholar
• Eskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15(1):107.
   PubMedGoogle Scholar
• Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated rejection (BORTEJECT). J Am Soc Nephrol. 2018;29(2):591–605.
   PubMed Web of Science ®Google Scholar
• Kwun J, Burghuber C, Manook M, et al. Humoral compensation after bortezomib treatment of allosensitized recipients. J Am Soc Nephrol. 2017;28(7):1991–1996.
   PubMed Web of Science ®Google Scholar
• NCT02201576. Bortezomib in rejection of kidney transplants (TRIBUTE). Bethesda (MD): U.S. National Library of Medicine; 2014 [ updated Sept 16, 2020; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02201576
   Google Scholar
• NCT03737136. Comparison between bortezomib and rituximab plus plasmapheresis in AMR. Bethesda (MD): U.S. National Library of Medicine; 2018 [ updated Jan 28, 2022; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03737136
   Google Scholar
• Burghuber CK, Manook M, Ezekian B, et al. Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. Am J Transplant. 2019;19(3):724–736.
   PubMed Web of Science ®Google Scholar
• Ezekian B, Schroder PM, Mulvihill MS, et al. Pretransplant desensitization with costimulation blockade and proteasome inhibitor reduces dsa and delays antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. J Am Soc Nephrol. 2019;30(12):2399–2411.
   PubMed Web of Science ®Google Scholar
• Mayer KA, Doberer K, Eskandary F, et al. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. Curr Opin Organ Transplant. 2021;26(1):97–105.
   PubMed Web of Science ®Google Scholar
• Joher N, Matignon M, Grimbert P. HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol. 2021;12:688301.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149–1155.
   PubMed Web of Science ®Google Scholar
• Kwun J, Matignon M, Manook M, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol. 2019;30(7):1206–1219.
   PubMed Web of Science ®Google Scholar
• Spica D, Junker T, Dickenmann M, et al. daratumumab for treatment of antibody-mediated rejection after abo-incompatible kidney transplantation. Case Rep Nephrol Dial. 2019;9(3):149–157.
   PubMed Web of Science ®Google Scholar
• Doberer K, Kläger J, Gualdoni GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation. 2021;105(2):451–457.
   PubMed Web of Science ®Google Scholar
• NCT05021484. Felzartamab in late antibody-mediated rejection. Bethesda (MD): U.S. National Library of Medicine; 2021 [ updated Aug 25, 2021; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT05021484
   Google Scholar
• Mayer KA, Budde K, Halloran PF, et al. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 2022;23(1):270.
   PubMed Web of Science ®Google Scholar
• NCT04610320. Daratumumab-SC for highly sensitized patients awaiting heart transplantation. Bethesda (MD): U.S. National Library of Medicine; 2020 [ updated September 21, 2021; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04610320
   Google Scholar
• NCT04204980. Desensitization in kidney allograft using daratumumab (DARDAR). Bethesda (MD): U.S. National Library of Medicine; 2019 [ updated May 21, 2020; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04204980
   Google Scholar
• NCT04294459. Safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. Bethesda (MD): U.S. National Library of Medicine; 2020 [ updated Jan 24, 2022; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04294459
   Google Scholar
• NCT04827979. Daratumumab and belatacept for desensitization (ATTAIN). Bethesda (MD): U.S. National Library of Medicine; 2021 [ updated Jan 28, 2022; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04827979
   Google Scholar
• NCT05145296. the safety/efficacy of daratumumab with belatacept in highly HLA-sensitized patients awaiting kidney transplantation (COMBAT). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated Dec 6, 2021; cited 2021; cited Feb 25, 2022 Dec 6, 2021; cited Feb 6, 2021; cited Feb 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT05145296
   Google Scholar
• Waiser J, Duerr M, Budde K, et al. Treatment of acute antibody-mediated renal allograft rejection with cyclophosphamide. Transplantation. 2017;101(10):2545–2552.
   PubMed Web of Science ®Google Scholar
• NCT01630538. cyclophosphamide therapy for refractory antibody-mediated rejection (AMR) in kidney transplants. Bethesda (MD): U.S. National Library of Medicine; 2012 [ updated Apr 19, 2018; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01630538
   Google Scholar
• NCT02546492. Treatment of chronic antibody-mediated rejection in kidney transplant with acthar (TGActhar). Bethesda (MD): U.S. National Library of Medicine; 2015 [ updated Feb 10, 2022; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02546492
   Google Scholar
• NCT03991780. Fostamatinib in the treatment of chronic active antibody mediated rejection (FOSTAMR). Bethesda (MD): U.S. National Library of Medicine; 2019 [ updated Oct 4, 2021; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03991780
   Google Scholar
• Tempest-Roe S, Prendecki M, McAdoo SP, et al. Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. Sci Rep. 2022;12(1):3330.
   PubMed Web of Science ®Google Scholar
• Benazzo A, Worel N, Schwarz S, et al. Outcome of extracorporeal photopheresis as an add-on therapy for antibody-mediated rejection in lung transplant recipients. Transfus Med Hemother. 2020;47(3):205–213.
   PubMed Web of Science ®Google Scholar
• Augusto JF, Gatault P, Sayegh J, et al. Successful treatment of acute kidney allograft rejection using extracorporeal photopheresis in the context of post-transplant lymphoproliferative diseases: three successive cases. Transpl Int. 2021;34(11):2415–2417.
   PubMed Web of Science ®Google Scholar
• Gregorini M, Del Fante C, Pattonieri EF, et al. photopheresis abates the anti-hla antibody titer and renal failure progression in chronic antibody-mediated rejection. Biology (Basel). 2021;10:6.
   Google Scholar
• NCT04870437. Impact of extracorporeal phototherapy (ECP) on auxiliary follicular T-lymphocytes and circulating B-lymphocytes during chronic antibody-mediated rejection in kidney transplantation. (IPECAM). Bethesda (MD): U.S. National Library of Medicine; 2021 [ updated May 3, 2021; cited Feb 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04870437
   Google Scholar
• NCT03585855. Mesenchymal stem cell transplantation in the treatment of chronic antibody mediated kidney graft rejection (ABMR). Bethesda (MD): U.S. National Library of Medicine; 2018 [ updated Jul 25, 2019; cited Feb 22, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03585855
   Google Scholar
• Veceric-Haler Z, Kojc N, Sever M, et al. Case report: capillary leak syndrome with kidney transplant failure following autologous mesenchymal stem cell therapy. Front Med (Lausanne). 2021;8:708744.
   PubMed Web of Science ®Google Scholar
• Schinstock CA, Sapir-Pichhadze R, Naesens M, et al. Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications. Am J Transplant. 2019;19(1):123–131.
   PubMed Web of Science ®Google Scholar
• Schinstock CA, Askar M, Bagnasco SM, et al. A 2020 banff antibody-mediated injury working group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study. Transpl Int. 2021;34(3):488–498.
   PubMed Web of Science ®Google Scholar
• Loupy A, Aubert O, Orandi BJ, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ. 2019;366:l4923.
   PubMedGoogle Scholar
• Naesens M, Loupy A, Hilbrands L, et al. Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation. Transpl Int. 2022;35:10137.
   PubMed Web of Science ®Google Scholar
• Mühlbacher J, Schörgenhofer C, Doberer K, et al. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021;34(8):1542–1552.
   PubMed Web of Science ®Google Scholar
• Devresse A, De Greef J, Yombi JC, et al. and SARS-CoV-2 infection in kidney transplant recipients. Transplant Direct. 2022;8(3):e1292.
   PubMed Web of Science ®Google Scholar
• Duettmann W, Naik MG, Zukunft B, et al. eHealth in transplantation. Transpl Int. 2021;34(1):16–26.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015;67(10):2591–2600.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, Berman A, et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 2016;68(9):2163–2173.
   PubMed Web of Science ®Google Scholar
• Hwang SS, Cannom RR, Abbas MA, et al. Diverticulitis in transplant patients and patients on chronic corticosteroid therapy: a systematic review. Dis Colon Rectum. 2010;53(12):1699–1707.
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–2617.
   PubMed Web of Science ®Google Scholar
• Nguyen VP, Kobashigawa JA. Antibody-medicated rejection after heart transplantation: diagnosis and clinical implications. Curr Opin Organ Transplant. 2020;25(3):248–254.
   PubMed Web of Science ®Google Scholar
• Halverson LP, Hachem RR. Antibody-mediated rejection and lung transplantation. Semin Respir Crit Care Med. 2021;42(3):428–435.
   PubMedGoogle Scholar